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Abstract 
Background: Perivascular spaces (PVS) have an important role in the elimination of metabolic waste from the brain. 
It has been hypothesized that the enlargement of PVS (ePVS) could be affected by pathophysiological mechanisms 
involved in Alzheimer’s disease (AD), such as abnormal levels of CSF biomarkers. However, the relationship between 
ePVS and these pathophysiological mechanisms remains unknown.
Objective: We aimed to investigate the association between ePVS and CSF biomarkers of several pathophysiological 
mechanisms for AD. We hypothesized that ePVS will be associated to CSF biomarkers early in the AD continuum (i.e., 
amyloid positive cognitively unimpaired individuals). Besides, we explored associations between ePVS and demo‑
graphic and cardiovascular risk factors.
Methods: The study included 322 middle‑aged cognitively unimpaired participants from the ALFA + study, many 
within the Alzheimer’s continuum. NeuroToolKit and Elecsys® immunoassays were used to measure CSF Aβ42, Aβ40, 
p‑tau and t‑tau, NfL, neurogranin, TREM2, YKL40, GFAP, IL6, S100, and α‑synuclein. PVS in the basal ganglia (BG) and 
centrum semiovale (CS) were assessed based on a validated 4‑point visual rating scale. Odds ratios were calculated 
for associations of cardiovascular and AD risk factors with ePVS using logistic and multinomial models adjusted for 
relevant confounders. Models were stratified by Aβ status (positivity defined as Aβ42/40 < 0.071).
Results: The degree of PVS significantly increased with age in both, BG and CS regions independently of cardiovas‑
cular risk factors. Higher levels of p‑tau, t‑tau, and neurogranin were significantly associated with ePVS in the CS of Aβ 
positive individuals, after accounting for relevant confounders. No associations were detected in the BG neither in Aβ 
negative participants.
Conclusions: Our results support that ePVS in the CS are specifically associated with tau pathophysiology, neurode‑
generation, and synaptic dysfunction in asymptomatic stages of the Alzheimer’s continuum.
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Background
Perivascular spaces (PVS) [1, 2], also known as Virchow-
Robin spaces, facilitate CSF transport from the basal cis-
terns into the brain interstitial fluid (ISF) [3] and have an 
important role in the elimination of metabolic waste and 
fluid from the brain [4]. Interestingly, water influx into 
the CSF flow through PVS could play a role equivalent 
to the one in the lymphatic system and it recently gained 
substantial attention due to its relation to amyloid-β (Aβ) 
clearance [5–7]. Indeed, enlargement of PVS (ePVS) may 
result in impaired ISF drainage and has been shown to 
be associated with cerebral amyloid angiopathy in cogni-
tively impaired patients [8, 9], and with peripheral neu-
roinflammatory biomarkers in the elderly [10, 11]. The 
impairment of this biological mechanism might contrib-
ute to the development of AD pathophysiology, charac-
terized by Aβ plaques and tau tangles. On top of these, 
several other pathophysiological mechanisms have been 
shown to be altered in preclinical AD stages [12].
The main hypothesis of our study was to investigate 
whether altered levels of CSF AD biomarkers were asso-
ciated with ePVS in a sample of middle-aged cognitively 
unimpaired participants, many within the Alzheimer’s 
continuum. The term “Alzheimer’s continuum” is applied 
as an umbrella term that includes both “Alzheimer’s path-
ological change” and “Alzheimer’s disease” as defined in 
the NIA-AA Research Framework nomenclature [13]. 
The term “Alzheimer’s pathologic change” is used when 
there is evidence of Aβ pathology but not tau, whereas 
the term “Alzheimer’s disease” is applied whenever there 
is evidence of both Aβ and tau pathology, regardless of 
the clinical manifestations.
We first explored the association between PVS with 
demographic and cardiovascular-related risk factors and 
assessed the dependency of the results with Aβ status. 
Moreover, we sought for associations between PVS with 
additional CSF biomarkers of several pathophysiologi-
cal mechanisms involved in AD and other neurodegen-
erative disorders such as axonal damage (NfL), synaptic 
dysfunction (neurogranin), microglial (sTREM2), astro-
glial-related response (GFAP, YKL40, S100), other neuro-
inflammatory biomarkers (IL6), and α-synuclein.
Material and methods
Participants
The study included participants from the ALFA study 
(Alzheimer and Families) at the Barcelonaβeta Brain 
Research Center [14], which aims at studying the pre-
clinical stage of AD. The ALFA study (Clinicaltrials.gov 
Identifier: NCT01835717) includes 2743 cognitively 
unimpaired participants, including a high proportion of 
AD patients’ offspring, aged between 45 and 75  years. 
In this study, a subset of 322 participants from a 
nested study (ALFA + ; NCT02485730) was included. 
ALFA + individuals were invited based on their specific 
AD risk profile. This AD profile was determined by an 
algorithm in which participants’ AD parental history, 
age, number of APOE-ε4, alleles, verbal episodic memory 
score, and CAIDE (Cardiovascular Risk Factors, Aging, 
and Incidence of Dementia) score were taken into con-
sideration. These individuals are cognitively unimpaired 
and, therefore, are in the preclinical stage of the Alzhei-
mer’s continuum. In terms of main demographic char-
acteristics, the percentages do not differ from the ALFA 
parent cohort. In addition, all individuals included in this 
study have available information on APOLIPOPROTEIN 
E (APOE) genotype, MRI examination, CSF biomarker 
levels, as well as cardiovascular risk factors (Fig.  1). 
Notice that the average time range between MRI acqui-
sition and CSF sampling was 44  days (± 57  days). MRI 
acquisition and cognitive assessment were performed at 
the same visit.
Image acquisition
Scans were obtained with a 3  T scanner (Ingenia CX, 
Philips, Amsterdam, Netherlands). The MRI protocol 
was identical for all participants and included high-res-
olution 3D T2-weighted image: Turbo Spin Echo (TSE), 
voxel size 1 × 1x1  mm3, repetition time/echo time (TR/
TE): 2500/264  ms, flip angle = 90°. In addition, a 3D 
T1-weighted Turbo Field Echo (TFE) sequence was 
acquired (voxel size 0.75 × 0.75 × 0.75  mm, TR/TE: 
9.90/4.6  ms, flip angle = 8°) as well as a 3D T2-FLAIR 
sequence (TSE, voxel size 1 × 1x1 mm, TR/TE/TI: 
5000/312/1700  ms). Scans were visually assessed for 
quality and incidental findings by a trained neuroradiolo-
gist. T1w images were segmented to compute total gray 
matter volume and total intracranial volume (TIV) using 
Freesurfer 6.0 (https:// surfer. nmr. mgh. harva rd. edu/). 
In addition, white matter hyperintensities (WMH) were 
segmented from FLAIR images using the Lesion Segmen-
tation Toolbox (LST; https:// www. appli ed- stati stics. de/ 
lst. html) for SPM12 [15].
Rating of perivascular spaces
PVS were evaluated by a radiologist using the visual 
rating scale developed by [16] based on T2-weighted 
images. The radiologist was blind to clinical assessment 
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and quantification of variables of interest used in the 
study. Briefly, PVSs were quantified independently in 
two brain regions, including BG, and centrum semio-
vale (CS). PVS in BG and CS were assessed in the slice 
and hemisphere with the highest number and rated as 
0 (no PVS; degree 0), 1 (mild; 1–10 PVS; degree 1), 2 
(moderate; 11–20 PVS; degree 2), 3 (frequent; 21–40 
PVS; degree 3), or 4 (severe; > 40 PVS; degree 4). Exam-
ples of the PVS rating are given in Fig.  2. Participants 
were dichotomized according to the severity of the 
ePVS rating of the BG and CS (degrees 0–2 were cat-
egorized as non-severe or 0, degrees 3–4 were catego-
rized as severe or 1).
The intra-rater agreement rate (Cohen’s Kappa) of 
PVS rating was evaluated by estimating the intraclass 
correlation of two independent ratings from the same 
radiologist on a random sample of 20% of the sub-
jects in the dataset. The intra-rater agreement analysis 
showed substantial reliability (κ = 0.77, p = 6.02e − 08 
for BG subscale; and κ = 0.76, p = 8.2e − 10 for CS 
subscale).
CSF collection and measurement
The collection of CSF and measurement of biomarkers 
in ALFA + was previously described comprehensively 
[12]. In brief, CSF t-tau and p-tau were measured using 
the electrochemiluminescence immunoassays Elecsys® 
Total-tau CSF and phosphor-tau(181P) CSF on a fully 
automated cobas e601 instrument (Roche Diagnos-
tics International Ltd.). The rest of the CSF biomarkers 
were measured with robust prototype assay as part of 
the NeuroToolKit (Roche Diagnostics International Ltd, 
Rotkreuz, Switzerland) on both cobas e 601 and e 411 
instruments. All measurements were performed at the 
Clinical Neurochemistry Laboratory, Sahlgrenska Uni-
versity Hospital, Mölndal, Sweden.
Aβ pathology positivity (Aβ +) was defined by CSF 
Aβ42/40 ratio. We derived the cutoffs for each of these 
biomarkers using a two-Gaussian mixture modeling. 
The cut-off was defined as the mean plus 2 standard 
deviations (SD) of the non-pathologic Gaussian distri-
bution (i.e., the Gaussian with the higher mean value for 
Aβ42/40 ratio and the resulting cutoff was 0.071. This 
Fig. 1 Flow chart that shows the selection of the participants of the study. ALFA study, ALzheimer and FAmilies; PVS, perivascular spaces; CSF, 
cerebrospinal fluid; BG, basal ganglia; CS, centrum semiovale; N, sample
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approach for the definition of Aβ + has been shown to be 
optimal for the detection of pathophysiological changes 
in early stages of the Alzheimer’s continuum [17]. A total 
of 122 individuals in the study were categorized as Aβ + .
Risk factors assessment
Sociodemographic and clinical data were collected dur-
ing face-to-face interviews by trained neuropsycholo-
gists, study nurses, and clinical neurologists. Participants’ 
systolic and diastolic blood pressure were measured 
twice and the second measure was used. Total choles-
terol level was obtained from a blood test (lipoprotein 
panel). Body mass index (BMI) was derived from the 
height and weight measured at the time of the interview. 
Physical activity was measured using the Spanish short 
version of the Minnesota Leisure Time Physical Activ-
ity Questionnaire [18] and participants were split into 
two categories: “active” (more than 150  min of moder-
ate exercise or 75  min of vigorous exercise per week as 
recommended by the American Heart Association) or 
‘inactive’. Participants with systolic blood pressure levels 
above 140 mmHg, self-reported hypertension diagnosis, 
or current use of anti-hypertensive medication were con-
sidered hypertensive. Diabetes and dyslipidemia status 
were defined from participant self-reported diagnosis. 
Moreover, based on these cardiovascular factors, we cal-
culated a dementia risk score CAIDE (Cardiovascular 
Risk Factors, Aging, and Incidence of Dementia) to be 
included in the analysis. Further details of the calculation 
of CAIDE can be found in [19]. The APOE allelic variants 
ε2, ε3, and ε4 were determined from allelic combinations 
of the rs429358 and rs7412 polymorphisms, where the ε4 
allele is the combination of the C allele at both sites [20]. 
Individuals were classified according to the number of ε4 
alleles (non-carriers, heterozygotes, homozygotes). Allele 
frequencies and departures from Hardy–Weinberg equi-
librium were inspected.
Statistical analysis
Differences between the degree of PVS in demographic 
and cardiovascular variables were assessed using χ2 tests 
(categorical variables), one-way ANOVA (normal contin-
uous variables), and/or non-parametric Kruskal–Wallis 
tests (non-normal continuous variables).
There were differences in demographics and cardiovas-
cular factors between the degrees of PVS. Therefore, odd 
ratios were calculated for associations of potential risk 
factors with ePVS. Associations between CSF biomark-
ers and ePVS (higher degree of PVS) were examined in 
logistic regressions (BG-ePVS) and multinomial regres-
sions (CS-ePVS) adjusting for the previous potential 
confounders selected through stepwise regression (back-
ward method) to generate minimally adjusted models. All 
regression models were adjusted by age, sex, APOE-ɛ4 
status, physical inactivity, total GM volume, and TIV. 
BG-ePVS models were additionally adjusted by systolic 
blood pressure, and CS-ePVS models were additionally 
adjusted by diastolic blood pressure.
Analyses with CSF biomarkers were stratified by Aβ 
status, as defined by CSF Aβ42/40 ratio, to assess whether 
the relationship between ePVS and CSF biomarker levels 
differed between individuals with normal (negative) and 
pathologic (positive) Aβ levels. We first examined asso-
ciations between ePVS and a non-pathological biomarker 
(Aβ40) to assess whether ePVS might be associated with 
overall protein clearance by CSF. We then sought associa-
tions between ePVS and the rest of CSF biomarkers with 
and without correction for Aβ40. This has been the final 
model selected in the study. All these models were cor-
rected by relevant demographic and cardiovascular fac-
tors previously identified.
Notice that, categories of ePVS with less than 20 obser-
vations were included in the former category [individuals 
with degree 3 in BG-ePVS (N = 19), and degree 4 in CS-
ePVS (N = 10). As a post hoc analysis, we excluded these 
categories, and we reproduced regression models and 
compared them with previous analyses to evaluate the 
Fig. 2 Perivascular spaces rating. A Score of 1 in basal ganglia 
(non‑severe). B Score of 4 in basal ganglia (severe). C Score of 1 
(non‑severe) in centrum semiovale. D Score of 4 (severe) in centrum 
semiovale. Circle: an enlarged Perivascular Space
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risk of overfitting (these models produced similar results 
and were not presented).
Statistical significance was set at P ≤ 0.05 and corrected 
using pair-wise correction (group comparisons) and false 
discovery rate (FDR) (association models). All statistical 




The mean age of the study’s participants was 60.4 (± 4.9) 
years old, and 64.5% were female. Degree 2 of ePVS was 
the most frequent in both BG and CS (between 42 and 
44% of participants). In contrast, degree 3 in BG (5.7%), 
and degree 4 in CS (3.01%) were less commonly encoun-
tered among participants. In addition, we did not find 
participants with degree 4 in BG (Fig.  3). Further char-
acteristics of the sample and the distribution of poten-
tial risk factors according to ePVS degree are shown in 
Table  1. Characteristics of the CSF biomarker sample 
according to ePVS degree are shown in Table 2, and char-
acteristics of the sample stratified by Aβ42/40 status are 
shown in Supplemental Table 1.
Association between demographics and cardiovascular 
risk factors on ePVS
Table  3 shows associations between demographic 
and cardiovascular risk factors with BG-ePVS and 
Fig. 3 Distribution of Perivascular Spaces by degree of severity. Legend: BG, Basal Ganglia; CS, centrum semiovale. Model 1 shows associations 
correcting by age, sex and cardiovascular risk factors. Model 2 shows associations correcting by age, sex, cardiovascular risk factors and Aβ40. Blue 
color intensities indicate the magnitude of the associations (higher levels of biomarkers). Abbreviations: AD, Alzheimer’s disease; PVS, perivascular 
spaces; BG, basal ganglia; CS, centrum semiovale; CSF, cerebrospinal fluid; Aβ40, amyloid‑β 40; Aβ42, amyloid‑β 42; GFAP, glial fibrillary acidic protein; 
IL6, interleukin‑6; NfL, neurofilament light; p‑tau, phosphorylated tau; sTREM2, soluble triggering receptor expressed on myeloid cells 2 (TREM2); 
t‑tau, total tau
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CS-ePVS. We observed that the degree of PVS signifi-
cantly increased with age in both, BG and CS regions 
(BG, OR [CI95%]: 1.14 [1.07, 1.23]; CS, degree 2 vs degree 
1, OR [CI95%]: 1.11 [1.01,1.2]; degree 3 + 4 vs 1, OR 
[CI95%]: 1.27 [1.13,1.45]; degree 3 + 4 vs 2, OR [CI95%]: 
1.16 [1.05, 1.28]).
In the CS region, specific significant predictors of 
increasing PVS degree were higher diastolic blood 
pressure, and higher WMH (degree 3 + 4 vs degree 1, 
OR[CI95%]: 1.02[1.01, 1.03]; degree 3 + 4 vs degree 1, 
OR[CI95%]: 1.33[1.06, 1.67]) (Supplemental Table  2). 
However, they were not significant after adjusting for 
additional risk factors (Table  3). Interestingly, females, 
who did not show significant associations in individual 
models, presented higher risk for CS-ePVS after adjust-
ing for cardiovascular risk factors (degree 3 + 4 vs degree 
1, OR [CI95%]: 5.5 [1.59, 21.06]). Finally, we did not find 
a significant association between the risk of ePVS and the 
number of APOE-ε4 alleles.
Table. 1 Characteristics of the sample and group comparisons of potential risk factors across degrees of Perivascular Spaces in Basal 
Ganglia and Centrum Semiovale Regions. Legend: N, sample size; n, count of individuals for each categorical variable; SD, standard 
deviation; ePVS, enlarged perivascular spaces; BG, basal ganglia; CS, centrum semiovale; CAIDE, Cardiovascular Risk Factors, Aging and 
Incidence of Dementia; BMI, body mass index; WMH, white matter hyperintensities; GM, gray matter volume; TIV, total intracranial 
volume
BG-ePVS CS-ePVS





2 + Degree 3 
(n = 160)




Degree 3 + 4 
(n = 85)
p value
Sex, n (%) 322 0.156 0.549
Male 118 (36.6%) 66 (40.7%) 52 (32.5%) 35 (38.9%) 56 (38.1%) 27 (31.8%)
Female 204 (63.4%) 96 (59.3%) 108 (67.5%) 55 (61.1%) 91 (61.9%) 58 (68.2%)




Non‑carriers 156 (48.4%) 72 (44.4%) 84 (52.5%) 43 (47.8%) 75 (51.0%) 38 (44.7%)
Carriers 166 (51.6%) 90 (55.6%) 76 (47.5%) 47 (52.2%) 72 (49.0%) 47 (55.3%)
Education (years) 318 13.4 (3.50) 13.6 (3.39) 13.2 (3.61) 0.346 13.3 (3.22) 13.8 (3.50) 12.9 (3.76) 0.188
Diabetes, n (%) 304 0.531 0.161
No 294 (96.7%) 141 (95.9%) 153 (97.5%) 77 (93.9%) 137 (98.6%) 80 (96.4%)
Yes 10 (3.29%) 6 (4.08%) 4 (2.55%) 5 (6.10%) 2 (1.44%) 3 (3.61%)
Dyslipidemia, n (%) 304 0.406 0.551
No 159 (52.3%) 81 (55.1%) 78 (49.7%) 47 (57.3%) 71 (51.1%) 41 (49.4%)
Yes 145 (47.7%) 66 (44.9%) 79 (50.3%) 35 (42.7%) 68 (48.9%) 42 (50.6%)
BMI (kg/m2) 322 27.0 (4.16) 27.5 (4.34) 26.4 (3.91) 0.014 27.8 (4.64) 26.8 (3.72) 26.5 (4.27) 0.077
Systolic Blood Pres‑
sure (mmHg)
321 133 (15.9) 131 (14.9) 135 (16.4) 0.007 131 (14.9) 133 (15.2) 135 (17.7) 0.228
Diastolic Blood 
Pressure(mmHg)
321 75.4 (9.89) 75.7 (9.56) 75.1 (10.2) 0.541 74.1 (9.80) 75.1 (9.80) 77.2 (9.97) 0.100
Cholesterol (mg/
dL)




Non‑active 55 (19.1%) 20 (14.6%) 35 (23.2%) 12 (15.8%) 24 (17.8%) 19 (24.7%)
Active 233 (80.9%) 117 (85.4%) 116 (76.8%) 64 (84.2%) 111 (82.2%) 58 (75.3%)
CAIDE score (0–15) 286 6.00 [4.00;7.00] 5.00 [4.00;7.00] 6.00 [4.00;7.00] 0.129 5.00 [4.00;7.00] 5.00 [4.00;6.00] 6.00 [4.75;7.00] 0.089













WMH (ml) 257 3.33 (16.6) 1.43 (1.72) 5.08 (22.9) 0.068 1.39 (1.39) 4.83 (23.7) 2.48 (2.84) 0.346
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Table. 2 Characteristics of the sample of CSF biomarkers across degrees of perivascular spaces. Legend: N, sample size; n, count of 
individuals for each categorical variable; SD, standard deviation; BG, basal ganglia; CS, centrum semiovale; ePVS, enlarged perivascular 
spaces
BG-ePVS CS-ePVS
N Mean (SD) Degree 1 
(n = 162)
Degree 
2 + Degree 3 
(n = 160)




Degree 3 + 4 
(n = 85)
p value
Aβ42 (pg/mL) 322 1374 (604) 1287 (520) 1462 (669) 0.009 1321 (637) 1392 (538) 1399 (677) 0.616




Negative 200 (62.1%) 93 (57.4%) 107 (66.9%) 50 (55.6%) 100 (68.0%) 50 (58.8%)
Positive 122 (37.9%) 69 (42.6%) 53 (33.1%) 40 (44.4%) 47 (32.0%) 35 (41.2%)
p‑Tau (pg/mL) 312 16.8 (7.67) 15.4 (6.08) 18.2 (8.77) 0.001 15.1 (5.70) 16.4 (6.60) 19.1 (10.2) 0.002
t‑Tau (pg/mL) 322 202 (73.6) 186 (61.6) 217 (81.4)  < 0.001 184 (61.5) 198 (66.1) 227 (90.1)  < 0.001
GFAP (pg/mL) 322 7.66 (2.72) 7.46 (3.00) 7.87 (2.39) 0.167 7.22 (2.13) 7.43 (2.55) 8.54 (3.32) 0.002
YKL40 (pg/mL) 322 150 (55.3) 136 (45.7) 165 (60.3)  < 0.001 139 (52.6) 145 (46.1) 171 (66.7)  < 0.001
TREM2 (pg/mL) 322 8.04 (2.28) 7.55 (2.02) 8.54 (2.41)  < 0.001 7.73 (2.22) 7.85 (2.18) 8.69 (2.38) 0.008
IL6 (pg/mL) 322 4.08 (2.04) 4.20 (2.16) 3.97 (1.90) 0.311 4.12 (1.92) 4.08 (2.35) 4.03 (1.55) 0.960
NFL (pg/mL) 322 83.4 (36.7) 78.8 (27.7) 88.1 (43.6) 0.024 82.5 (48.4) 79.8 (25.5) 90.6 (38.2) 0.093
Neurogranin 
(pg/mL)
322 816 (339) 740 (299) 893 (359)  < 0.001 716 (301) 809 (306) 933 (394)  < 0.001
S100 (pg/mL) 322 1.02 (0.24) 1.02 (0.25) 1.03 (0.23) 0.722 0.99 (0.22) 1.01 (0.21) 1.07 (0.29) 0.080
α‑Synuclein (pg/
mL)
322 245 (277) 212 (180) 278 (347) 0.035 199 (147) 249 (265) 286 (381) 0.108
Table. 3 Associations between enlargement of perivascular spaces in basal ganglia and centrum semiovale regions, and 
demographic and cardiovascular risk factors. Legend: n, count of individuals for each categorical variable; SD, standard deviation; BG, 
basal ganglia; CS, centrum semiovale; ePVS, enlarged perivascular spaces; WMH, white matter hyperintensities; GM, gray matter volume; 
TIV, total intracranial volume; OR, odds ratio; CI, confidence interval
BG-ePVS CS-ePVS
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Degree 2 + 3 vs Degree 1 Degree 2 vs Degree 1 Degree 3 + 4 vs Degree 1 Degree 3 + 4 vs Degree 2
Sex, n (%)
  Male Ref Ref Ref Ref
  Female 1.29 [ 0.65, 3.04] 2.32 [0.88, 6.33] 5.5 [1.59, 21.06] 3.61 [1.39, 9.92]
  Age (years) 1.14 [1.07, 1.23] 1.1 [1.01, 1.20] 1.27 [1.13, 1.45] 1.16 [1.05, 1.28]
APOE‑ε4 allele carriers, n(%)
  Non‑carriers Ref Ref Ref Ref
  Heterozygous 1.07 [0.59, 2.19] 1.03 [0.49, 2.23] 0.86 [0.31, 2.41] 0.99 [ 0.45, 2.11]
  Homozygous 1.33 [0.50, 6.34] 0.57 [0.17, 2.01] 0.72 [0.10, 4.03] 5.03 [0.86, 31.43]
  Systolic blood pressure (mmHg) 1.02 [0.99, 1.01] 1.02 [0.98, 1.06]
  Diastolic blood pressure (mmHg) 1.06 [1.004, 1.12] 1.02 [0.98, 1.06]
Physical activity, n (%)
  Non‑active Ref Ref Ref Ref
  Active 0.52 [0.26, 1.27] 0.78 [ 0.31, 1.87] 0.48 [0.13, 1.69] 0.98 [0.41, 2.46]
  Total GM  (mm3) 1.0001 [0.99, 1.001] 1.0001 [0.99, 1.001] 1.0001 [1.0001, 1.001] 1.0001 [0.99, 1.00001]
  WMH (ml) 1.17 [1.0001, 1.45] 1.07 [0.91, 1.31] 1.08 [0.82, 1.47] 1.001 [0.99,1.01]
  TIV  (mm3) 1.0001 [0.99, 1.001] 0.999 [0.99, 1.001] 1.0001 [0.99, 1.00001] 1.0001 [0.99, 1.00001]
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Association between CSF biomarkers on ePVS
Models that were not corrected by Aβ40 levels showed 
that higher levels of p-tau (OR [CI95%]: 1.08 [1.02, 
1.15]), t-tau (OR [CI95%]: 1.01 [1.004, 1.01]), YKL40 (OR 
[CI95%]: 1.02 [1.01, 1.02]), sTREM2 (OR [CI95%]: 1.23 
[1.07, 1.43]), and neurogranin (OR [CI95%]: 1.003 [1.001, 
1.004]) were significantly associated with ePVS in the BG 
region. Only higher levels of CSF NfL (OR [CI95%]: 1.04 
[1.008, 1.08]) and neurogranin (OR [CI95%]: 1.003 [1.001, 
1.005]) were significantly associated with BG-ePVS 
in Aβ + individuals. In the CS region, we showed that 
higher levels of p-tau (OR [CI95%]: 1.08 [1.012, 1.16]), 
t-tau (OR [CI95%]: 1.01 [1.002, 1.018]), and neurogra-
nin (OR [CI95%]: 1.002 [1.001, 1.004]) were significantly 
associated with ePVS (Supplemental Table 3, Supplemen-
tal Figure 1). Moreover, we found significant associations 
between higher levels of CSF Aβ40 and a higher degree of 
PVS in both the BG and CS in the whole sample that per-
sisted when stratifying the analyses by Aβ status. After 
correcting for levels of CSF Aβ40, significant associations 
between higher levels of CSF p-tau (OR [CI95%]: 1.16 
[1.03, 1.35]), t-tau (OR [CI95%]: 1.02 [1.01, 1.04]), and 
neurogranin (OR [CI95%]: 1.004 [1.001, 1.008]) (degree 2 
vs degree 3 + 4) were found in the Aβ + group, only in the 
CS region (Table 4).
Discussion
This study aimed to assess whether pathophysiological 
processes related to AD, as measured by CSF biomarkers, 
are associated with higher degree of ePVS in a cohort of 
cognitively unimpaired individuals enriched for positive 
AD biomarkers.
We found that ePVS in the CS were associated with 
higher levels of CSF p-tau, t-tau, and neurogranin in 
Aβ + participants. CSF p-tau, t-tau and neurogranin are 
widely accepted biomarkers of tau protein pathophysi-
ology, neurodegeneration, and synaptic dysfunction, 
respectively. These associations between AD biomarkers 
and ePVS survived after correcting for relevant demo-
graphic and cardiovascular risk factors, as well as CSF 
Aβ40 levels. CSF Aβ40 concentration values are typically 
used to normalize CSF Aβ42 levels to render a superior 
performance (Aβ42/40 ratio) in discriminating patients 
with AD [21, 22]. Since it has been described that ePVS 
alter CSF dynamics, it could be hypothesized that ePVS 
may also alter the concentrations of proteins in the CSF. 
We found significant associations between higher ePVS 
levels and higher concentrations of CSF Aβ40, independ-
ent of Aβ status, thus supporting this hypothesis. In addi-
tion, in models not accounting for CSF Aβ40, higher 
ePVS levels were associated with higher levels of most 
of the CSF biomarkers, irrespective of the stratification 
by Aβ status. This finding suggests that levels of these 
CSF markers may be altered due to impaired CSF clear-
ance and not necessarily due to the involvement of these 
pathophysiological mechanisms in the development of 
ePVS. Furthermore, we stratified the analyses in Aβ + and 
Aβ- individuals to study the associations between ePVS 
and CSF biomarkers within and outside the Alzheimer’s 
continuum. Therefore, the fact that p-tau, t-tau, and neu-
rogranin survived the correction for CSF Aβ40 levels in 
Aβ + individuals supports the association of ePVS with 
core AD pathophysiological mechanisms.
We observed that the risk of ePVS was strongly asso-
ciated with age. The effect of age was not specific to a 
given region but was equally significant in both, CS and 
BG. In turn, the effect was independent of cardiovascular 
risk factors. Regarding sex differences in the distribution 
of ePVS, we observed a significant association specific to 
the CS region, suggesting that women have a higher risk 
of ePVS in this region dependent on cardiovascular risk 
factors, perhaps because of specific sex-related mecha-
nisms that also affect the formation of ePVS. Interest-
ingly, we did not find significant results for the BG region, 
in line with previous work reporting differences in ePVS 
formation according to the brain region and sex [7, 23].
We additionally found a significant association between 
risk of ePVS and WMH and systolic blood pressure in 
BG, as well as WMH and diastolic blood pressure in CS, 
which are in line with previous studies [24, 25]. Blood 
pressure effects were age-dependent and disappeared in 
both regions when correcting for demographic variables. 
Previous studies have also described strong associations 
between ePVS with increasing age and hypertension, but 
despite that, these analyses revealed that when all those 
variables were considered jointly, only age remained sig-
nificant, as in the present study [26, 27]. In addition, we 
found no significant associations between WMH and 
ePVS after adjusting for other risk factors, which has 
been also reported recently [6].
Recent studies have hypothesized that additional risk 
factors (e.g., genetic risk factors) may contribute to a 
larger portion of extracellular Aβ clearance, influencing 
the relationship between ePVS and CSF biomarkers [28]. 
Because APOE-ε4 enhances Aβ deposition [29], several 
studies focused on associations between APOE geno-
types and ePVS, with controversial results. In studies car-
ried out in older individuals and/or high cardiovascular 
risk, significant differences were found [30, 31]. Contrary 
to them, some studies performed in healthy younger 
individuals were in line with our results and did not find 
significant associations between APOE and ePVS [27, 
32]. Notice that even though our sample is enriched for 
APOE-ε4 carriers, they are relatively young and have a 
very low cardiovascular risk. In this context, additional 
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Table. 4 Associations Perivascular Spaces in Basal Ganglia and Centrum Semiovale and CSF biomarkers (logistic and multinomial 
regressions). Models were adjusted by potential demographic and cardiovascular risk factors, as well as, levels of Aβ40. Models were 
stratified by Aβ42/40 positive status. Legend: n, sample size; SD, standard deviation; ePVS, enlarged Perivascular Spaces; BG, Basal Ganglia; 
CS, Centrum Semiovale; NTK, NeuroToolKit; CSF, cerebrospinal fluid. 
All Individuals Aβ42/40 positivity (N=122) Aβ42/40 negativity (N=200)
Outcome Biomarker OR IC Biomarker OR IC Biomarker OR IC
BG (degree 2+3 vs 
degree 1)
Aβ42/40 0.059 [0.025, 0.626] Aβ42/40 Aβ42/40
BG (degree 2+3 vs 
degree 1)
p-Tau (pg/mL) 0.980 [0.925,1.055] p-Tau (pg/mL) 1.022 [0.937,1.161] p-Tau (pg/mL) 0.887 [0.74,1.061]
BG (degree 2+3 vs 
degree 1)
t-Tau (pg/mL) 0.999 [0.991,1.008] t-Tau (pg/mL) 1.004 [0.992,1.022] t-Tau (pg/mL) 0.992 [0.974,1.011]
BG (degree 2+3 vs 
degree 1)
GFAP (pg/mL) 0.883 [0.762,0.998] GFAP (pg/mL) 0.873 [0.589,1.254] GFAP (pg/mL) 0.895 [0.758,1.021]
BG (degree 2+3 vs 
degree 1)
YKL40 (pg/mL) 1.008 [0.999,1.018] YKL40 (pg/mL) 1.006 [0.987,1.026] YKL40 (pg/mL) 1.010 [0.999,1.023]
BG (degree 2+3 vs 
degree 1)
TREM2 (pg/mL) 1.082 [0.917,1.285] TREM2 (pg/mL) 1.127 [0.814,1.583] TREM2 (pg/mL) 1.072 [0.873,1.325]
BG (degree 2+3 vs 
degree 1)
IL6 (pg/mL) 1.108 [0.943,1.324] IL6 (pg/mL) 1.192 [0.854,1.708] IL6 (pg/mL) 1.119 [0.918,1.413]
BG (degree 2+3 vs 
degree 1)
NFL (pg/mL) 1.000 [0.986,1.014] NFL (pg/mL) 1.031 [0.998,1.07] NFL (pg/mL) 0.991 [0.974,1.009]




1.001 [0.999,1.004] Neurogranin (pg/
mL)
1.002 [0.999,1.007] Neurogranin (pg/
mL)
1.001 [0.998,1.005]
BG (degree 2+3 vs 
degree 1)
S100 (pg/mL) 0.850 [0.177,4.13] S100 (pg/mL) 1.782 [0.086,42.126] S100 (pg/mL) 0.810 [0.115,5.683]




1.001 [0.999,1.002] α-Synuclein (pg/
mL)
1.004 [1,1.018] α-Synuclein (pg/
mL)
1.000 [0.999,1.002]
CS (degree 2 vs 
degree 1)
Aβ42/40 0.001 [0.00001, 0.0017] Aβ42/40 Aβ42/40
CS (degree 2 vs 
degree 1)
p-Tau (pg/mL) 0.960 [0.878,1.055] p-Tau (pg/mL) 1.064 [0.905,1.301] p-Tau (pg/mL) 0.824 [0.669,1.003]
CS (degree 2 vs 
degree 1)
t-Tau (pg/mL) 0.995 [0.984,1.005] t-Tau (pg/mL) 1.006 [0.986,1.028] t-Tau (pg/mL) 0.984 [0.964,1.004]
CS (degree 2 vs 
degree 1)
GFAP (pg/mL) 0.935 [0.806,1.085] GFAP (pg/mL) 1.025 [0.673,1.558] GFAP (pg/mL) 0.921 [0.78,1.095]
CS (degree 2 vs 
degree 1)
YKL40 (pg/mL) 0.997 [0.988,1.006] YKL40 (pg/mL) 1.010 [0.99,1.033] YKL40 (pg/mL) 0.992 [0.981,1.003]
CS (degree 2 vs 
degree 1)
TREM2 (pg/mL) 0.899 [0.755,1.067] TREM2 (pg/mL) 0.883 [0.636,1.208] TREM2 (pg/mL) 0.911 [0.724,1.143]
CS (degree 2 vs 
degree 1)
IL6 (pg/mL) 1.016 [0.866,1.21] IL6 (pg/mL) 1.098 [0.722,1.759] IL6 (pg/mL) 0.991 [0.825,1.212]
CS (degree 2 vs 
degree 1)
NFL (pg/mL) 0.992 [0.979,1.002] NFL (pg/mL) 0.992 [0.962,1.024] NFL (pg/mL) 0.992 [0.974,1.002]




1.001 [0.998,1.003] Neurogranin (pg/
mL)
1.003 [0.998,1.009] Neurogranin (pg/
mL)
1.000 [0.997,1.004]
CS (degree 2 vs 
degree 1)
S100 (pg/mL) 0.960 [0.189,5.014] S100 (pg/mL) 0.445 [0.018,11.609] S100 (pg/mL) 1.155 [0.146,9.506]




1.003 [1,1.007] α-Synuclein (pg/
mL)
1.013 [0.998,1.038] α-Synuclein (pg/
mL)
1.003 [1,1.007]
CS (degree 3+4 vs 
degree 1)
Aβ42/40 ~0 [0,0.8373] Aβ42/40 Aβ42/40
CS (degree 3+4 vs 
degree 1)
p-Tau (pg/mL) 1.010 [0.946,1.112] p-Tau (pg/mL) 1.152 [0.986,1.487] p-Tau (pg/mL) 0.814 [0.643,1.011]
CS (degree 3+4 vs 
degree 1)
t-Tau (pg/mL) 1.000 [0.992,1.011] t-Tau (pg/mL) 1.013 [0.996,1.039] t-Tau (pg/mL) 0.982 [0.959,1.003]
CS (degree 3+4 vs 
degree 1)
GFAP (pg/mL) 1.021 [0.876,1.217] GFAP (pg/mL) 1.280 [0.77,2.285] GFAP (pg/mL) 1.009 [0.853,1.226]
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studies become essential and relevant for the near future 
in this field of research.
Several limitations must be considered for this study. 
Particularly challenging was the evaluation of MRIs with 
very small ePVS that can be seen as faint, indistinct high 
signal structures since those can cause a change from one 
category to another if considered. This difficulty has been 
previously described [8] and addressed by maintaining a 
general impression of the region and trying to match it 
with the categories provided. Moreover, although several 
PVS rating methods have been developed, we restricted 
our study to a single rating scale using only a single MRI 
protocol and limiting the quantification of PVS to two 
brain regions. Also, dichotomization of PVS scales could 
cause a substantial reduction in statistical power, thus 
increasing the change of false negatives in our results. 
Another limitation stems from the fact that CSF bio-
markers showed a high correlation among them in our 
sample. In particular, p-tau, t-tau, and neurogranin had 
pair-wise Pearson’s r > 0.90. This high correlation might 
reflect a tight association between tau pathophysiology, 
AD-related neurodegeneration, and synaptic dysfunction 
in our sample or be due to other technical or physiologi-
cal confounding factors. Nevertheless, p-tau measure-
ments obtained with the same essay have been shown to 
be able to predict clinical decline and conversion to AD 
[33] and have been approved for clinical use [34]. Finally, 
even though the associations between ePVS and p-tau, 
t-tau, and neurogranin in Aβ + individuals survived the 
correction for Aβ40 levels, Aβ40 cannot be interpreted 
Table. 4 (continued)
All Individuals Aβ42/40 positivity (N=122) Aβ42/40 negativity (N=200)
Outcome Biomarker OR IC Biomarker OR IC Biomarker OR IC
CS (degree 3+4 vs 
degree 1)
YKL40 (pg/mL) 1.002 [0.993,1.012] YKL40 (pg/mL) 1.010 [0.989,1.036] YKL40 (pg/mL) 0.999 [0.988,1.01]
CS (degree 3+4 vs 
degree 1)
TREM2 (pg/mL) 1.017 [0.808,1.279] TREM2 (pg/mL) 1.008 [0.643,1.604] TREM2 (pg/mL) 1.051 [0.78,1.421]
CS (degree 3+4 vs 
degree 1)
IL6 (pg/mL) 1.118 [0.885,1.429] IL6 (pg/mL) 1.485 [0.898,3.101] IL6 (pg/mL) 1.079 [0.763,1.484]
CS (degree 3+4 vs 
degree 1)
NFL (pg/mL) 0.994 [0.982,1.004] NFL (pg/mL) 1.002 [0.972,1.039] NFL (pg/mL) 0.994 [0.977,1.004]




1.001 [0.999,1.004] Neurogranin (pg/
mL)
1.003 [0.999,1.009] Neurogranin (pg/
mL)
1.000 [0.996,1.005]
CS (degree 3+4 vs 
degree 1)
S100 (pg/mL) 0.403 [0.047,3.219] S100 (pg/mL) 1.286 [0.017,113.076] S100 (pg/mL) 0.322 [0.02,4.771]




1.004 [1,1.011] α-Synuclein (pg/
mL)
1.016 [0.999,1.051] α-Synuclein (pg/
mL)
1.003 [0.997,1.01]
CS (degree 3+4 vs 
degree 2)
Aβ42/40 0.000 [0,0.01349] Aβ42/40 Aβ42/40
CS (degree 3+4 vs 
degree 2)
p-Tau (pg/mL) 1.037 [0.981,1.108] p-Tau (pg/mL) 1.158 [1.032,1.351] p-Tau (pg/mL) 0.954 [0.797,1.135]
CS (degree 3+4 vs 
degree 2)
t-Tau (pg/mL) 1.004 [0.997,1.012] t-Tau (pg/mL) 1.020 [1.005,1.041] t-Tau (pg/mL) 0.996 [0.977,1.015]
CS (degree 3+4 vs 
degree 2)
GFAP (pg/mL) 1.083 [0.963,1.234] GFAP (pg/mL) 1.355 [0.961,2.05] GFAP (pg/mL) 1.065 [0.934,1.229]
CS (degree 3+4 vs 
degree 2)
YKL40 (pg/mL) 1.005 [0.997,1.013] YKL40 (pg/mL) 1.006 [0.991,1.022] YKL40 (pg/mL) 1.006 [0.996,1.016]
CS (degree 3+4 vs 
degree 2)
TREM2 (pg/mL) 1.112 [0.939,1.322] TREM2 (pg/mL) 1.231 [0.906,1.719] TREM2 (pg/mL) 1.036 [0.831,1.294]
CS (degree 3+4 vs 
degree 2)
IL6 (pg/mL) 1.072 [0.904,1.268] IL6 (pg/mL) 1.371 [0.954,2.11] IL6 (pg/mL) 0.993 [0.783,1.217]
CS (degree 3+4 vs 
degree 2)
NFL (pg/mL) 1.009 [0.996,1.023] NFL (pg/mL) 1.008 [0.985,1.032] NFL (pg/mL) 1.012 [0.993,1.031]




1.002 [1,1.003] Neurogranin (pg/
mL)
1.004 [1.001,1.008] Neurogranin (pg/
mL)
1.002 [0.999,1.005]
CS (degree 3+4 vs 
degree 2)
S100 (pg/mL) 0.505 [0.094,2.614] S100 (pg/mL) 0.548 [0.028,8.746] S100 (pg/mL) 0.476 [0.051,4.062]




1.000 [0.999,1.001] α-Synuclein (pg/
mL)
1.001 [1,1.004] α-Synuclein (pg/
mL)
0.999 [0.996,1.001]
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as a valid marker of overall cerebral protein clearance in 
physiological conditions. However, the fact that the bio-
markers that survive correction for Aβ40 are also signifi-
cant without it strongly argues for our main result to be 
robust against this correction.
A strength of our study is the use of high-resolution 
T2 MRI scans and a small voxel size (1  mm3, isotropic), 
recommended for PVS rating [8]. An additional sub-
stantial strength is our sample-based design, which is a 
large cohort of cognitively unimpaired individuals after 
an exhaustive neuropsychological and clinical screen-
ing procedure. In addition, results are not likely to be 
severely confounded by comorbidities of dementia, 
being the individuals of the study at a low mean cardio-
vascular risk. The studied cohort has a high prevalence 
of APOE-ε4 carriers, thus bringing a higher statistical 
power in comparison with studies with a similar number 
of individuals that are genetically closer to the general 
population [35]. Our sample also has a high prevalence 
of positive CSF Aβ, individuals compared with other 
studies.
In conclusion, our findings showed, for the first time, an 
association between ePVS in the CS and higher levels of 
CSF core AD biomarkers p-tau and t-tau, as well as CSF 
neurogranin, in cognitively unimpaired Aβ + individuals. 
This result supports the association between ePVS and 
specific AD pathophysiological mechanisms occurring in 
the early stages of the Alzheimer’s continuum.
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